Short-Chain Fatty Acids (SCFAs) and Pulmonary Fibrosis: Could Gut Metabolites Influence Lung Fibrosis?
What Do Gut Bacteria Have to Do With Lung Fibrosis?
When researchers discuss the gut–lung axis, one of the most important questions is not simply:
Which bacteria live in the gut?
A potentially more useful question is:
What are those bacteria producing?
The intestinal microbiome functions almost like a large metabolic organ.
Gut microorganisms break down components of food that human digestive enzymes cannot fully process and transform them into biologically active compounds.
Among the most important of these compounds are short-chain fatty acids, or SCFAs.
The three principal SCFAs are:
acetate
propionate
butyrate
These substances are produced largely through bacterial fermentation of dietary carbohydrates, particularly fermentable fibers and resistant starches.
SCFAs are best known for their role in intestinal health.
But their influence does not stop at the intestinal wall.
They can affect immune cells, inflammatory pathways, epithelial barriers and gene expression, creating a plausible mechanism through which the gut microbiome could influence distant organs—including the lungs.
This has generated considerable interest in pulmonary fibrosis.
Recent reviews of the gut–lung axis identify SCFAs as some of the most important microbial metabolites potentially capable of modifying inflammatory and fibrotic pathways. (PubMed)
However, an important distinction must be made from the beginning:
Evidence that SCFAs influence fibrosis biology does not mean that taking an SCFA supplement has been proven to treat pulmonary fibrosis in humans.
Most therapeutic evidence remains preclinical.
What Are Short-Chain Fatty Acids?
Short-chain fatty acids are organic acids produced predominantly in the colon when gut bacteria ferment carbohydrates that escape digestion in the small intestine.
The main SCFAs are:
Acetate
Usually the most abundant SCFA in the colon and circulation.
Propionate
Used partly by the liver and involved in metabolic and immune signaling.
Butyrate
A major energy source for colonocytes and one of the most intensively studied microbiome metabolites in immune regulation and epithelial-barrier health.
These compounds do considerably more than supply calories.
They act as signaling molecules.
SCFAs can interact with receptors such as:
GPR41
GPR43
GPR109A
They can also influence gene expression through mechanisms such as histone deacetylase inhibition, particularly in the case of butyrate.
This allows the gut microbiome to influence human physiology without bacteria themselves needing to leave the intestine.
How Are SCFAs Produced?
Dietary fibers reach the colon, where bacteria ferment them.
Different bacterial communities possess different metabolic capabilities.
For example, some organisms are particularly efficient at producing butyrate, while others generate acetate that may then be used by other microbes through a process called cross-feeding.
Therefore, SCFA production depends on more than simply how much fiber a person eats.
It also depends on:
microbiome composition
substrate availability
intestinal transit
cross-feeding between organisms
colonic pH
medications
gastrointestinal disease
dietary patterns
This is one reason microbiome biology cannot be reduced to a simple equation such as:
more fiber = more butyrate = better health.
Human biology is more complex.
Why Are SCFAs Important to the Gut–Lung Axis?
SCFAs may influence pulmonary health through several pathways.
These include:
intestinal-barrier integrity
systemic immune regulation
macrophage behavior
Treg and Th17 balance
inflammatory signaling
epigenetic regulation
oxidative stress
fibroblast activation
Recent pulmonary-fibrosis literature increasingly focuses on these mechanisms. (PubMed Central (PMC))
SCFAs and the Intestinal Barrier
The intestinal lining is designed to allow nutrient absorption while preventing uncontrolled movement of microbial products into circulation.
Proteins such as:
occludin
claudins
ZO-1
help maintain tight junctions between intestinal epithelial cells.
SCFAs—particularly butyrate—can support epithelial metabolism and tight-junction integrity.
This may reduce passage of inflammatory microbial molecules into systemic circulation.
Why could that matter to pulmonary fibrosis?
Because greater exposure to microbial products such as lipopolysaccharide, or LPS, may stimulate systemic inflammatory responses capable of influencing the lung.
About Dr. Samar Shadly
Dr. Samar Shadly is a Consultant Pulmonologist and Certified Functional Medicine Practitioner, with advanced subspecialty training in interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and lung transplantation, together with expertise in functional and integrative medicine.
Her approach combines evidence-based pulmonary medicine with a broader assessment of factors that may influence a patient’s overall health, including nutrition, gastrointestinal health, the gut microbiome, metabolic health, lifestyle, and relevant environmental exposures.
A particular focus of her work is the emerging field of Integrative and Functional Pulmonology, especially in pulmonary fibrosis and autoimmune-associated interstitial lung disease. Her goal is to bridge conventional respiratory medicine with scientifically grounded integrative strategies, while clearly distinguishing established clinical evidence from promising but still experimental research.
Living with Pulmonary Fibrosis or Interstitial Lung Disease?
If you are looking for a more comprehensive assessment that combines specialist pulmonary expertise with a functional and integrative perspective, you can explore whether this approach may be appropriate for your individual condition.
To learn more about consultation options or request an assessment, contact us through the consultation page or WhatsApp.
Integrative care is intended to complement—not replace—evidence-based pulmonary treatment and should always be individualized according to the diagnosis and clinical situation.